Measles, because of the high rate of deaths and mental crippling, stands high on the list of need for an effective vaccine. First significant progress toward development of a practicable vaccine was made by Enders et al.1 who grew the virus in various cell culture systems and in embryonated eggs and effected an attenuation of virulence for man. Although the vaccine, given alone, regularly induced antibodies against measles 2 and afforded protection against the natural disease,3,4 the mild measles reactions caused by the vaccine were sufficiently great to preclude general patient and physician acceptance.
To minimize such reactions, McCrumb et al.5 and our group 6 gave the live measlesvirus vaccine followed immediately by a modifying dose of human immune globulin. This effected a marked suppression in clinical response without reduction in seroconversion rate or in the protective efficacy of the vaccine.5-7
The present communication details the findings
STOKES J, WEIBEL R, HALENDA R, REILLY CM, HILLEMAN MR. Enders' Live Measles-Virus Vaccine with Human Immune Globulin: Clinical Reactions. Am J Dis Child. 1962;103(3):366–372. doi:10.1001/archpedi.1962.02080020378037
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: